傑龍 GERN 深 滬
等待開盤 02-05 09:30:00 美东时间
1.47
-0.040
-2.65%
華盛通- 最 高1.5285
- 今 開1.50
- 成交量 1044.62万股
- 最 低 1.455
- 昨 收 1.51
- 總市值 9.38亿
- 52周最高 2.70
- 市盈率 靜 --
- 換手率 1.64%
- 52周最低 1.04
- 委 比 53.48%
- 總股本 6.38亿
- 歷史最高 7.79
- 量 比 0.63
- 振 幅 4.87%
- 歷史最低 0.75
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Geron shares are trading higher after the company announced FY26 financial guidance.
Geron shares are trading higher after the company announced FY26 financial guid...
01-13 02:46
Geron Issues 2026 Guidance Emphasizing RYTELO Growth
The latest update is out from Geron ( ($GERN) ). On January 12, 2025, Geron Cor...
01-12 21:47
Geron forecasts top-line growth, lower operating spend for 2026
Geron (GERN) expects 2026 net product revenue in the range of $220M to $240M from its telomerase inhibitor RYTELO (imetelstat). RYTELO (imetelstat) is approved in the U.S. and the European Union for t...
01-12 21:46
Geron Corporation Provides 2026 Financial Guidance
Geron Corporation announced its 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million. The company aims to drive commercial growth in the U.S., expand RYTELO into LR-MDS markets globally, and advance its Phase 3 IMpactMF trial. Financial guidance reflects expected top-line growth alongside reduced operating expenses, supporting Geron...
01-12 13:00
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted stock options to a newly hired employee, totaling 320,000 shares, with an exercise price of $1.34 per share. The options vest over four years, with 12.5% after six months and the remainder equally over 42 months, subject to continued employment. The awards comply with Nasdaq Listing Rule 5635(c)(4) and Geron's 2018 Inducement Award Plan.
2025-12-18 21:30
Geron strategic restructuring plan focuses on Rytelo growth
Geron said that as part of its strategic restructuring plan, it will focus on boosting growth of anemia treatment Rytelo (imetelestat) in the US, expanding availability of the drug into other countrie...
2025-12-17 06:49
Geron Implements Strategic Restructuring, Cutting Workforce By One-Third And Incurring ~$18M In Charges
On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its
2025-12-17 05:11
Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and
2025-12-08 21:09
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
2025-12-05 01:20
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
